Your Health, We Care
Another Name非戈替尼、Jyseleca、Fequintinib
IndicationsAdult patients with moderate to severe rheumatoid arthritis (RA) who have insufficient or intolerant response to various disease modifying antirheumatic drugs (DMARD).
Specs
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
Filgotinib is a prescription drug targeting Janus kinase 1 (JAK1). It was first approved for marketing in the European Union and Japan in September 2020. It should be used strictly under medical supervision.
Janus kinase 1 (JAK1)
Route and frequency of administration for filgotinib: Oral, once daily.
The dosage of filgotinib should be adjusted according to the patient's actual condition. For specific adjustments, consult a physician and follow medical advice.
Recommended reading: Dosage and Administration of Filgotinib
Common side effects: Nausea, upper respiratory tract infections, etc.
Serious side effects: Serious infections (e.g., pneumonia), herpes zoster, etc.
Reference article: Side Effects of Filgotinib
Pregnancy: Filgotinib is contraindicated in pregnant patients.
Lactation: It is unknown whether this drug is excreted into human milk. Breastfeeding women should not use filgotinib.
1. Before treatment, a comprehensive evaluation by a specialist is mandatory, with strict screening for contraindications and close monitoring during therapy.
2. Filgotinib is primarily metabolized by the CES2 enzyme. Caution is required when co-administered with CES2 inhibitors (e.g., simvastatin).
3. During treatment and for a period before and after, live vaccines are prohibited.
from FDA，2023.07
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
